Full-Time

Director – Translational Pathology

Confirmed live in the last 24 hours

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$195k - $220kAnnually

+ Bonus + Equity Incentive Plan

Senior, Expert

San Bruno, CA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Word/Pages/Docs
Data Analysis
Requirements
  • DVM, PhD with a minimum of 10 years post-graduate experience
  • Board certifications in anatomic pathology
  • DABT certification
  • 10+ years of hands-on pathology experience in an academic or industrial setting, along with significant prior supervisory experience managing multiple reports
  • Knowledge and experience with LIMS/ELN/HALO Link software and familiarity with the whole slide-scanning platform
  • Proven experience with multiple successful regulatory filings (e.g., IND/CTA, NDA/BLA) as a subject matter expert for pathology/toxicology, in vivo pharmacology, and nonclinical sections.
  • In-depth knowledge and understanding of comparative anatomy and pathology (e.g., human, non-human primate, rodents) and its application in general oncology, immunology, and toxicology
  • Ability to identify physiological and pathological changes in any tissue/cell types in multiple species and ability to accurately assess toxicologically vs. pharmacologically related events, test vs. test system-related events
  • Up-to-date knowledge of common and emerging tissue-based pathology, toxicology, and biomarker research platforms, including multiplex immunofluorescence.
  • Ability to adopt digital pathology for highly quantitative data-rich analysis.
  • In-depth and up-to-date understanding of relevant regulatory and GxP requirements.
  • Nonclinical safety assessment (toxicology) support for development programs (designing, advising, reviewing the study plans, and integrating toxicology assessment of Lyell’s development candidates)
  • Strong understanding of immunology, T-cell biology, and immunotoxicology. Strong ability to investigate nonclinical safety-related (adverse) events in nonclinical/clinical study settings
  • Strong collaboration, project management, data analysis, and scientific presentation skills
  • Proficiency in using office software such as Microsoft Word® PowerPoint® or equivalents to generate reports and presentations.
  • Strong verbal and written communication skills and capable of routinely interpreting data and presenting to diverse groups within Research and Development.
Responsibilities
  • Provide pathology support and oversee clinical pharmacodynamic biomarker assay development (patient biopsy sample assay for in situ characterization of therapeutic T cells and patient tumors to assess the effect of Lyell’s T cells products in the clinical trials)
  • Support multiple discovery stage research programs and early clinical development plans by designing and reporting appropriate studies for pathology analysis, tissue-based assay development, target expression profiling, tumor type selection/validation, and nonclinical safety (toxicity) assessment.
  • Provide pathology support for in vivo studies to assess the effect of novel T cells, platforms, and technologies and analysis of unexpected safety events in all nonclinical studies.
  • Effectively prioritize and manage study timelines and resource allocations with a deeper understanding of Lyell’s research projects and proprietary technologies.
  • Responsible for ensuring high-quality analysis, interpretation, and presentation of pathology data in research project team meetings.
  • Ensure timely and accurate collection of pathology study data in various databases and ELN and generate high-quality reports for external publications and regulatory filings.
  • Collaborate with facilities to maintain a well-functioning pathology lab that anticipates the needs of its users and our research organization.
  • Actively serve as a member of the Research leadership team and other leadership/cross-functional/managerial activities.
  • Successfully manage, mentor, and ensure career development of pathology team members.

Lyell Immunopharma develops advanced cell therapies specifically designed to treat solid tumors, which are cancerous tissue masses. Their approach focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. The company utilizes proprietary technologies, Gen-R and Epi-R, which involve genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and to ensure T cells can persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments for solid tumors, leveraging a diverse product pipeline and a team of experts in oncology and adoptive cell therapy. Their ultimate goal is to push the limits of current cancer treatments and provide effective solutions for patients where traditional therapies have not succeeded.

Company Stage

IPO

Total Funding

$479.6M

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-19%

2 year growth

-12%
Simplify Jobs

Simplify's Take

What believers are saying

  • Lyell's strategic partnerships, such as with MaxCyte and AWS, enhance their technological capabilities and operational efficiency.
  • The appointment of experienced leaders like Lynn Seely as CEO and Matthew Lang as Chief Business Officer strengthens the company's executive team.
  • Their state-of-the-art manufacturing facility in Bothell, Washington, supports the scalability and testing of their proprietary technologies.

What critics are saying

  • The company is still awaiting critical clinical data, which could impact investor confidence and future funding.
  • High turnover in key management positions, such as the departure of the General Counsel, may lead to strategic and operational disruptions.

What makes Lyell Immunopharma unique

  • Lyell Immunopharma focuses on T cell reprogramming to treat solid tumors, a niche area with fewer competitors compared to broader oncology treatments.
  • Their proprietary technologies, Gen-R and Epi-R, offer unique solutions to T cell exhaustion and lack of durable stemness, setting them apart from other cell therapy companies.
  • The company's commitment to scientific innovation is underscored by a world-class team of experts in oncology and adoptive cell therapy.

Help us improve and share your feedback! Did you find this helpful?